Research notes

Whilst the result was largely pre-released, the underlying 1HFY24 EBIT of $20.0m reflects a significant improvement on the $4.4m achieved in the pcp. The construction materials division was the primary driver, where EBIT increased 95% on the pcp as improved prices, volumes and cost control saw EBIT margins increase to 11.8% (1H23: 7.4%). The result really points to the cyclical nature of the industry and WGN’s leverage to an improving cycle. The positive operating environment, combined with continued M&A across the industry (ABC, BLD, CSR all receiving bids) all bode well for WGN. On this basis we have changed our recommendation to an ADD rating (previously Speculative Buy) reflecting lower earnings and valuation risk, whilst leaving our target price unchanged at $1.15/sh.

MPL’s 1H24 underlying NPAT (A$263m) was +16% on the pcp, and -1% below company-compiled consensus (A$266m).  We saw this as a bit of a mixed result overall. Whilst the Health Insurance (HI) claims environment remains favourable, revised FY24 HI policyholder guidance and management expense growth guidance both disappointed. We make relatively nominal changes to our MPL FY24F/FY25F EPS of -1%/+2% reflecting lower claims forecasts, reduced policyholder growth expectations and higher HI operating expenses. Our PT is set at A$3.73 (previously A$3.76). The current operating environment still appears relatively favourable for MPL, but we see the stock as fair value trading on ~19x FY24F PE. HOLD maintained

PLS reported a soft 1H24 earnings result against consensus expectations, but given there was no significant news and the stock is highly shorted, the miss did not move the stock price greatly. 1H24 underlying EBITDA of A$415m was -8% vs Visible Alpha consensus, while underlying NPAT of A$273m was -15% vs consensus. P680 and P1000 projects are on schedule and budget. FY24 capex guidance reduce to manages costs. Maintain our Add rating with a $4.50ps Target Price. Besides the miss a quiet result for PLS. We expect the stock to re-rate in a broader lithium recovery.

We expect c.1% consensus EBITDA downgrades given first-time FY24 EBITDA guidance that at the mid-point indicates 9-10% growth over FY23. No change to DPS guidance. We layer in higher costs and capex beyond FY24. HOLD retained. 12 month target price $7./sh. At current prices, we estimate a 12 month TSR of c.-3% (incl. 6.9% cash yield) and a five year IRR of c.6% pa.

Expanding vertical integration remains a key ambition, with MIN focused on increasing the proportion of controllables in its business. A solid 1H24 underlying result, although with part of the strength driven by higher-than-expected revenue across iron ore and mining services. Management revealed plans to grow Onslow to 50mtpa, and a view it might achieve as much as 12x EBITDA on the partial sell down of its haul road. We maintain an Add rating with an updated A$71ps Target Price (was A$72).

QAL has seen FUM growth of 41% (yoy), with Fee Earning FUM increasing 25% (yoy), leaving c.$2.1bn of dry powder to underpin future earnings growth. The 1H24 result saw funds management revenue increase 25% (yoy), while principal income increased 31% (yoy) off strong underwriting volumes, to deliver underlying Group NPAT of $12.6m, up 24% on the pcp, 4.6% above our expectations and 3.0% above VA consensus. QAL continues to deliver organic earnings growth of c.25% pa (based on FY24 guidance), the growth centered on a nascent residential property cycle upswing driven by unmet housing demand, along with stabilising construction prices and apartment price growth restoring development feasibilities. It is on this basis that we reiterate our ADD recommendation with a $3.10/sh price target.

QAN reported a better than feared 1H24 result with underlying NPBT in line with consensus but down 12.8% on the pcp. Despite this, EPS only fell 3.2% reflecting the A$1bn of shares QAN has bought back since 1H23. Jetstar’s performance was the highlight of the result. Another A$400m share buyback was announced. QAN’s outlook commentary implies consensus needs to downgrade FY24 forecasts. Importantly, travel demand remains strong. With QAN trading on 5.8x FY24F P/E, we continue to think the stock is oversold. However its is lacking catalysts in the near-term with progress on its margin targets in FY25 likely the key for share price outperformance from here, in our view.

BGA’s 1H24 result was materially stronger than guidance following a much better than expected result from Bulk, despite it being loss making due to the material fall in global dairy prices and Australian processors overpaid for milk. Branded had a strong result. While seasonally 1H cashflow is weak, it was stronger than expected and so was BGA’s gearing metrics. Despite the result beat, FY24 guidance remains unchanged given the 1H benefited from some pull forward of sales across both businesses and in the 2H BGA is taking a conservative view on ‘out of home’ channels given the pressure the consumer is under. Albeit off a low base, we have made material upgrades to our NPAT forecast due to lower D&A and tax. After strong share price appreciation, we retain a Hold rating however we note there is material upside taking a medium-term view if BGA delivers its FY28 targets.

LOV is democratising jewellery. Its fashionable and attractively priced products are reaching and appealing to a larger and larger global audience. LOV has operations in over 40 markets and substantial white space to expand in almost all of them. The 1H24 result surpassed expectations, mainly due to strong gross margins, which were supported by favourable changes to the price architecture. We have increased our EBIT estimate for the current year by 4%, but, for us, it’s not about the near-term. The investor should focus on what this business could develop into in the years ahead. We reiterate our Add rating and increase our target price from $27.50 to $30.00.

IPH reported slightly below expectations: underlying NPAT +4.5% including acquisitions and currency. LFL revenue +2%; -2% EBITDA. Asia was expected to be weak, however came through weaker than expected at a -6.4% EBITDA. Australia showed some improvement with EBITDA growth of 1% on pcp and 4.5% hoh. Cashflow generation improved which was the highlight. A return of organic growth (which remains very subdued) is the key catalyst for IPH. Some early improvement has been seen in Australia, however Asia is now lagging. There is valuation support near-term and longer-term upside from acquisitions an strategy execution.